可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Azizi F, Rahmani M, Raiszadeh F, et al. Association of lipids, lipoproteins, apolipoproteins and paraoxonase enzyme activity with early onset coronary artery disease[J]. Coronary Artery Disease, 2002, 13(1):9-16.
[2]Nitter-Hauge S, Erikssen J, Thaulow E, et al. Angiographic and risk factor characteristics of subjects with early onset ischaemic heart disease[J]. Br Heart J, 1981, 46(3):325-330.
[3]Chen L, Chester M, Kaski JC, et al. Clinical Factors and Angiographic Features Associated With Early onset Coronary Artery Disease[J]. Chest, 1995, 108(2):364-369.
[4]Malmberg K, Bavenholm P, Hamsten A, et al. Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age[J]. J Am Coll Cardiol, 1994, 24(3):592-599.
[5]Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and the development of ischaemic heart disease[J].Lancet,1975, 1(7897):16-19.
[6]Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study[J]. JAMA, 1986, 256(20):2835-2838.
[7] Assmann G, Schulte H, von Eckardstein A, et al. High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport[J]. Atherosclerosis, 1996, 124(Suppl):S11-S20.
[8]Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis[J]. Circulation, 2004, 109(23Suppl 1):III8-III14.
[9] Ansell BJ, Fonarow GC, Fogelman AM. Highdensity lipoprotein: is it always atheroprotective?[J]. Curr Atheroscler Rep, 2006, 8(5):405-411.
[10]Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I[J]. Circulation, 2001, 104 (19):2376-2383.
[11]Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL-C formation[J]. Curr Opin Lipidol, 2005, 16(1):19-25.
[12]Sarwar N, Sattar N. Triglycerides and coronary heart disease: have recent insights yielded conclusive answers[J]. Curr Opin Lipidol, 2009, 20(4):275-281.
[13]Erqou S, Kaptoge S, Perry P, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality[J]. JAMA, 2009, 302(4):412-423.
[14]Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger[J]. JAMA, 1996, 276(7):544-548.
[15]Jeli-Ivanovic Z, Memon L, Spasojevic-Kalimanovska V, et al. Independent association of high serum uric acid concentration with angiographically defined coronary artery disease[J]. Tohoku J Exp Med, 2007, 211(4):369-377.
[16]Vekic J, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, et al. High serum uric acid and low-grade inflammation are associated with smaller LDL-C and HDL-C particles[J]. Atherosclerosis, 2009, 203(1):236-242.
[17]Alderman MH. Uric acid and cardiovascular risk[J]. Current Opinion in Pharmacology, 2002, 2(2):126-130.
[18]Otsuka T, Kawada T, Katsumata M, et al. High-sensitivity C-reactive protein is associated with the risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men[J]. Int J Cardiol, 2008, 129(2):245-250.
[19]Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents[J]. Clinical Chemistry, 2009, 55(2):256-264.
[20] Donner MG, Klein GK, Mathes PB, et al. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile[J]. Metabolism, 1998, 47(3):273-279.